National collection of membranous nephropathy cases in France
Official title: Immunopathological Analysis in a French National Cohort of Membranous Nephropathy (IHMN)
Run by Centre Hospitalier Universitaire de Nice · NCT04326218 · Data updated 2026-11-12
This project tests a one-year national collection of membranous nephropathy cases in France to learn about incidence, antibodies, outcomes, and risk factors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice, Alpes Maritime) |
| Status | Recruiting |
| Started | July 4, 2020 |
| Main results expected | June 3, 2031 |
| Study ends | December 3, 2031 |
| Registry record updated | June 16, 2026 |
| Trial ID | NCT04326218 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with biopsy-confirmed MN or positive anti-PLA2R1/anti-THSD7A serology who can give informed consent.
✕Probably not a fit
Patients with incorrect diagnosis, or those unable to consent, may not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a national cohort study enrolling adults with biopsy-confirmed membranous nephropathy or positive anti-PLA2R1/anti-THSD7A serology in France over a one-year period. Blood samples are collected to analyze antibodies and biomarkers, alongside clinical data such as outcomes after diagnosis or relapse and environmental risk factors. The aim is to map incidence, serology prevalence, prognosis, and potential genetic and environmental contributors to MN in a real-world, national context. Results may help validate previous findings from smaller studies and enhance understanding of MN in the French population.
Why it matters
Potential benefit: If successful, the study could improve understanding of MN patterns in France and guide future patient management and research.
How similar studies have gone: Previous monocentric studies on PLA2R1/THSD7A and MN pathways suggest that larger national collections can validate and extend findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or more * Biopsy on a native kidney consistent with MN and/or positivity for serum anti-PLA2R1 and/or anti-THSD7A antibodies * Signed informed consent Exclusion Criteria: * Diagnosis error based on the kidney biopsy staining or on serology analyses for the positivity for anti-PLA2R1 and/or anti-THSD7A * Patients unable to give an informed consent * Patients withdrawing an informed consent
Where it's running
-
CHU de Nice, Hôpital de l'Archet
Nice, Alpes Maritime, France Recruiting
Study contacts
- Principal investigator: Barbara Seitz-polski — Hopital de l'Archet laboratoire immunology, 151 route de sain-Antoine de Ginestière 06200 Nice
- Study coordinator: Barbara SEITZ-POLSKI, MD
- Email: seitz-polski.b@chu-nice.fr
- Phone: +33 4 92 03 55 02
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Rituximab plus Cyclosporine for Primary Membranous Nephropathy
This study tests whether adding Cyclosporine to Rituximab helps people with primary membranous nephropathy achieve remission of heavy protein in the urine faster.
-
HLX79 with rituximab (HLX01) for active glomerulonephritis
This trial will test whether adding HLX79 at different doses to rituximab (HLX01) helps adults with active membranous nephropathy or lupus nephritis.
-
Using Raman Spectroscopy to Diagnose Kidney Diseases
This study is testing a new way to diagnose kidney diseases by analyzing urine and blood samples from patients with specific kidney conditions to see if it can help identify the diseases more accurately.
-
Testing ManNAc for treating kidney disease FSGS
This study is testing if a new oral treatment called ManNAc can help adults with kidney disease FSGS by reducing protein levels in their urine and checking how safe it is over 12 weeks.
-
AI-guided personalized rituximab for membranous nephropathy
This trial will test whether an AI-guided approach to dosing rituximab improves remission in adults with PLA2R1-positive nephrotic membranous nephropathy.
-
Long-term outcomes in primary membranous nephropathy
This project will follow adults with primary membranous nephropathy and nephrotic syndrome to see how their disease and real-world treatments affect long-term kidney outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.